Axel Merseburger presents his round-up of the most interesting research on immunotherapy in renal cell carcinoma at the ESMO Congress 2019, including the TITAN RCC study and additional analyses from JAVELIN Renal 101 (3:14). This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

Axel Merseburger takes us through his top picks of the genitourinary cancer research reported at the ESMO Congress 2019, including updates on the TITAN and STAMPEDE prostate cancer trials, the SORCE trial in renal cell carcinoma, and the investigation of first-line enfortumab vedotin in bladder cancer (5:33).

Ross Camidge comments on the advanced non-small-cell lung cancer research that caught his attention at the ESMO Congress 2019, including the FLAURA and CheckMate 227 overall survival data, and updates on brigatinib and lorlatinib (3:01).

An update was presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, after a median 33.7 months of follow-up.

In the overall cohort, the proportion of patients who received treatment increased significantly from 69.0% in 2011 to 77.2% in 2019, as did the proportion receiving upfront ICI therapy, from 4.7% in 2015 to 45.6% in 2019.

The team concludes that “[t]he monitoring, diagnosis, and management of ILD/pneumonitis is an area of continuing improvement,” and refers clinicians to guidelines updated in 2019 on the dosing and supportive care required during T-DXd treatment. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group ESMO Open 2022; doi:10.1016/j.esmoop.2022.100554

Speaking at the 2020 Genitourinary Cancers Symposium in San Francisco, California, USA, Jonathan Rosenberg (Memorial Sloan Kettering Cancer Center, New York, USA) said that the initial results from this trial – presented previously at the ESMO Congress 2019   – “showed very promising activity in terms of objective response rates [ORR], suggesting that a potential platinum free approach in this patient population is warranted.”

The data from this cohort were reported in JAMA Oncology in 2019 .

These proportions increased to 40% and 58%, respectively, when postapproval QoL publications (to October 2019) were also considered.

Subgroup analyses reported at the ESMO Congress 2019 showed better outcomes with the combination than sunitinib in individuals with sarcomatoid histology tumors and those who did not receive upfront cytoreductive nephrectomy .

Studies presented at the ESMO 2019 Congress propose that patients with metastatic renal cell carcinoma may benefit from a combination of nivolumab and the VEGFR tyrosine kinase inhibitor tivozanib, or by continuing with single-agent nivolumab past initial disease progression.

Time spent off treatment could be used as a novel clinical trial endpoint for patients undergoing renal cell carcinoma immunotherapy, suggest study findings reported at the ESMO Congress 2019 in Barcelona, Spain.

Adding atezolizumab to chemotherapy significantly prolongs progression-free survival in the first-line advanced urothelial cancer setting, according to the IMvigor130 trial results presented at the ESMO Congress 2019.

Guillermo de Velasco discusses four posters presented at the ESMO Congress 2019 focusing on biomarker analyses of the ADAPTeR, JAVELIN Renal 101 and NIVOREN GETUG-AFU 26 trials (6:07). This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

The initial findings for the phase 2 study were reported at the ESMO Congress in 2019 and updated results have now been presented at the ESMO Virtual Congress 2020 by Yohann Loriot, from Institut Gustave Roussy in Villejuif, France.

By Laura Cowen medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group ESMO Congress 2019; Barcelona, Spain: 27 September–1 October Lancet Oncol 2019; doi:10.1016/S1470-2045(19)30620-5

By Shreeya Nanda medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group ESMO Congress 2019; Barcelona, Spain: 27 September–1 October

By Shreeya Nanda medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group ESMO Congress 2019; Barcelona, Spain: 27 September–1 October Ann Oncol 2019; doi:10.1093/annonc/mdz396

Shirish Gadgeel (University of Michigan, Ann Arbor, USA) presented the findings at the ESMO Congress 2019 in Barcelona, Spain.